Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells

Liu,Zebing; Yang,Yu; Zhang,Youyuan; Ye,Xuanguang; Wang,Li; Xu,Guoxiong

doi:10.3892/or.2013.2833

Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells

Authors:
- Zebing Liu
- Yu Yang
- Youyuan Zhang
- Xuanguang Ye
- Li Wang
- Guoxiong Xu
View Affiliations

Affiliations: Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, P.R. China, Central Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: November 4, 2013 https://doi.org/10.3892/or.2013.2833
Pages: 153-160

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Papillary thyroid cancer (PTC) accounts for 80-90% of all cases of thyroid malignancies. Stomatin-like protein 2 (SLP-2) is a novel member of the stomatin superfamily and is found in several types of human tumors. However, whether it is expressed in human PTC is unknown. In the present study, we aimed to explore the diagnostic value of SLP-2 in patients with PTC and to investigate whether SLP-2 expression is regulated by transforming growth factor-β (TGF-β), a cytokine which plays an important role in PTC tumorigenesis. A total of 107 patients consisting of 99 cases of classical and 8 cases of follicular variant PTC was examined. The expression of SLP-2 mRNA and protein was examined by immunohistochemistry (IHC) and qPCR, respectively. We found that SLP-2 was overexpressed in human PTC. The expression of SLP-2 was significantly associated with clinicopathological features of the PTC cases. Particularly, increased SLP-2 expression was mainly correlated with primary tumors >1 cm in size, with late stage tumors and with metastatic lymph nodes. The expression of SLP-2 was correlated with the expression of Ki-67, a cell proliferation marker, in PTC tissues as detected by IHC. SLP-2 was upregulated by TGF-β1 in PTC cells as evaluated by western blotting. The present data revealed for the first time that patients with PTC exhibited SLP-2 overexpression that was associated with clinicopathological features. The correlation between SLP-2 expression and proliferation marker Ki-67 may be characteristic of PTC and may reflect PTC progression. SLP-2 was upregulated by TGF-β1, indicating a possible role of SLP-2 in PTC tumorigenesis. Our data suggest that SLP-2 may be considered as a useful diagnostic marker and therapeutic target for PTC.

View Figures

View References

1	Boone RT, Fan CY and Hanna EY: Well-differentiated carcinoma of the thyroid. Otolaryngol Clin North Am. 36:73–90. 2003. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
3	Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
4	Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med. 338:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
5	French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP and Haugen BR: Tumor-associated lymphocytes and increased FoxP3⁺ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 95:2325–2333. 2010.PubMed/NCBI
6	Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M and Karpuzoglu G: Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS. 111:439–443. 2003. View Article : Google Scholar : PubMed/NCBI
7	Wang Y and Morrow JS: Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem. 275:8062–8071. 2000. View Article : Google Scholar : PubMed/NCBI
8	Christie DA, Kirchhof MG, Vardhana S, Dustin ML and Madrenas J: Mitochondrial and plasma membrane pools of stomatin-like protein 2 coalesce at the immunological synapse during T cell activation. PLoS One. 7:e371442012. View Article : Google Scholar : PubMed/NCBI
9	Owczarek CM, Treutlein HR, Portbury KJ, Gulluyan LM, Kola I and Hertzog PJ: A novel member of the STOMATIN/EPB72/mec-2 family, stomatin-like 2 (STOML2), is ubiquitously expressed and localizes to HSA chromosome 9p13.1. Cytogenet Cell Genet. 92:196–203. 2001. View Article : Google Scholar : PubMed/NCBI
10	Green JB and Young JP: Slipins: ancient origin, duplication and diversification of the stomatin protein family. BMC Evol Biol. 8:442008. View Article : Google Scholar : PubMed/NCBI
11	Tondera D, Grandemange S, Jourdain A, et al: SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J. 28:1589–1600. 2009. View Article : Google Scholar : PubMed/NCBI
12	Christie DA, Lemke CD, Elias IM, et al: Stomatin-like protein 2 binds cardiolipin and regulates mitochondrial biogenesis and function. Mol Cell Biol. 31:3845–3856. 2011. View Article : Google Scholar : PubMed/NCBI
13	Da Cruz S, Parone PA, Gonzalo P, et al: SLP-2 interacts with prohibitins in the mitochondrial inner membrane and contributes to their stability. Biochim Biophys Acta. 1783:904–911. 2008.PubMed/NCBI
14	Zhang L, Ding F, Cao W, et al: Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res. 12:1639–1646. 2006. View Article : Google Scholar
15	Song L, Liu L, Wu Z, et al: Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-κB/MMP-9 pathway. J Pathol. 226:534–543. 2012.PubMed/NCBI
16	Cao WF, Zhang LY, Liu MB, Tang PZ, Liu ZH and Sun BC: Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray. Hum Pathol. 38:747–752. 2007. View Article : Google Scholar
17	Cao W, Zhang B, Liu Y, et al: High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol. 128:430–436. 2007. View Article : Google Scholar : PubMed/NCBI
18	Han CL, Chen JS, Chan EC, et al: An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol Cell Proteomics. 10:M110.003087. 2011.PubMed/NCBI
19	Liu D, Zhang L, Shen Z, et al: Increased levels of SLP-2 correlate with poor prognosis in gastric cancer. Gastric Cancer. Jan 31–2013.(Epub ahead of print).
20	Wang Y, Cao W, Yu Z and Liu Z: Downregulation of a mitochondria associated protein SLP-2 inhibits tumor cell motility, proliferation and enhances cell sensitivity to chemotherapeutic reagents. Cancer Biol Ther. 8:1651–1658. 2009. View Article : Google Scholar
21	Eloy C, Santos J, Cameselle-Teijeiro J, Soares P and Sobrinho-Simões M: TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch. 460:587–600. 2012.PubMed/NCBI
22	Knauf JA, Sartor MA, Medvedovic M, et al: Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene. 30:3153–3162. 2011.PubMed/NCBI
23	Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED and Wynford-Thomas D: Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors. 2:149–155. 1990.
24	Müssig K, Wehrmann T, Dittmann H, et al: Expression of the proliferation marker Ki-67 associates with tumor staging and clinical outcome in differentiated thyroid carcinomas. Clin Endocrinol. 77:139–145. 2012.PubMed/NCBI
25	Kimura ET, Kopp P, Zbaeren J, et al: Expression of transforming growth factor β1, β2, and β3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Thyroid. 9:119–125. 1999.
26	Cui Z, Zhang L, Hua Z, Cao W, Feng W and Liu Z: Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma. Oncol Rep. 17:829–833. 2007.PubMed/NCBI
27	Christie DA, Mitsopoulos P, Blagih J, et al: Stomatin-like protein 2 deficiency in T cells is associated with altered mitochondrial respiration and defective CD4⁺ T cell responses. J Immunol. 189:4349–4360. 2012. View Article : Google Scholar : PubMed/NCBI
28	Da Cruz S, De Marchi U, Frieden M, Parone PA, Martinou JC and Demaurex N: SLP-2 negatively modulates mitochondrial sodium-calcium exchange. Cell Calcium. 47:11–18. 2010.PubMed/NCBI
29	Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al: The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 97:E878–E887. 2012. View Article : Google Scholar : PubMed/NCBI
30	Cao W, Zhang B, Ding F, Zhang W, Sun B and Liu Z: Expression of SLP-2 was associated with invasion of esophageal squamous cell carcinoma. PLoS One. 8:e638902013. View Article : Google Scholar : PubMed/NCBI
31	Massagué J: TGFβ in cancer. Cell. 134:215–230. 2008.
32	Montero-Conde C, Martin-Campos JM, Lerma E, et al: Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene. 27:1554–1561. 2008. View Article : Google Scholar : PubMed/NCBI
33	Vasko V, Espinosa AV, Scouten W, et al: Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA. 104:2803–2808. 2007. View Article : Google Scholar : PubMed/NCBI
34	Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, et al: The BRAF^V600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 69:8317–8325. 2009.